ImmuPharma (LON:IMM) Trading 39.7% Higher – Still a Buy?

ImmuPharma plc (LON:IMM)’s stock price was up 39.7% during trading on Monday . The company traded as high as GBX 7.20 ($0.10) and last traded at GBX 7.20 ($0.10). Approximately 16,765,875 shares changed hands during mid-day trading, an increase of 134% from the average daily volume of 7,166,685 shares. The stock had previously closed at GBX 5.16 ($0.07).

ImmuPharma Stock Up 18.7%

The stock has a market cap of £65.96 million, a P/E ratio of -1,483.15 and a beta of 1.53. The firm’s 50-day moving average is GBX 2.55 and its two-hundred day moving average is GBX 2.76.

ImmuPharma (LON:IMM) last posted its earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.